Digital Mammography Best for Young Women With Dense Breasts

News
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 1
Volume 16
Issue 1

New subgroup analyses from the Digital Mammographic Imaging Screening Trial (DMIST) Investigators Group confirm previous results that digital screening mammography is significantly more accurate than film screening mammography in young women with dense breasts but not in women overall.

CHICAGO—New subgroup analyses from the Digital Mammographic Imaging Screening Trial (DMIST) Investigators Group confirm previous results that digital screening mammography is significantly more accurate than film screening mammography in young women with dense breasts but not in women overall. Etta Pisano, MD, of the University of North Carolina School of Medicine, Chapel Hill, reported the data at the 2006 Radiological Society of North America meeting (abstract SSA15-02).

DMIST enrolled 49,528 women from 33 imaging centers in the US and Canada. All of the women had both digital and film mammography, interpreted by two readers. Findings were available for 42,760 women who underwent biopsy for a suspicious lesion or who had 1-year follow-up examination. Primary results from the study published in 2005 included 15 data analyses. The results presented at RSNA included 10 additional analyses.

The new analyses of DMIST data indicated that digital mammography was significantly better than film mammography for detecting breast cancer in one group of women—pre- or perimenopausal women with dense breast tissue (P = .0015). However, as in the original analyses, digital technology did not confer a diagnostic advantage in detecting breast cancer across-the-board. According to Dr. Pisano, subgroup analyses showed no significant difference between digital and analog mammography in breast cancer screening for any other segment of women classified by age, menopausal status, and breast density. The subgroup analyses also showed that analog mammography was slightly superior to digital technology for screening women over age 65 with fatty breasts, although the difference was not significant, she said.

Dr. Pisano believes the results favoring digital mammography in younger women with dense breasts may be due to differences in contrast. "My hypothesis is that contrast for digital mammography has been optimized for dense breasts, but not for fatty breasts," she said.

Recent Videos
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Administering oral SERD-based regimens may enhance patients’ quality of life when undergoing treatment for ER-positive, HER2-negative breast cancer.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
Related Content